ResearcherIowa State UniversityActive in the last 2 years
Brianna M. White
Matched on ORCID iD 0000-0001-6814-8341; OpenAlex author ID A5009544914. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 13
2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: 2 papers
Papers 4
- Niclosamide-Loaded Polyanhydride Nanoparticles to Combat Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1007/s40883-025-00394-0↗
- Niclosamide nanoparticles enhance pancreatic cancer sensitivity to gemcitabine via HIF-1α inhibition. Co-author DOI 10.1016/j.isci.2025.114088↗
- Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies. Co-author DOI 10.7150/thno.64805↗
- Emerging Role of miR-345 and Its Effective Delivery as a Potential Therapeutic Candidate in Pancreatic Cancer and Other Cancers. First author DOI 10.3390/pharmaceutics13121987↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Surinder K. Batra · 4 shared papers, 2021–2025 · strength 0.76
- Paper Niclosamide nanoparticles enhance pancreatic cancer sensitivity to gemcitabine via HIF-1α inhibition. DOI 10.1016/j.isci.2025.114088↗
- Paper Niclosamide-Loaded Polyanhydride Nanoparticles to Combat Gemcitabine Resistance in Pancreatic Cancer. DOI 10.1007/s40883-025-00394-0↗
- Paper Emerging Role of miR-345 and Its Effective Delivery as a Potential Therapeutic Candidate in Pancreatic Cancer and Other… DOI 10.3390/pharmaceutics13121987↗
- Nagabhishek Sirpu Natesh · 3 shared papers, 2021–2025 · strength 0.63
- Paper Niclosamide nanoparticles enhance pancreatic cancer sensitivity to gemcitabine via HIF-1α inhibition. DOI 10.1016/j.isci.2025.114088↗
- Paper Niclosamide-Loaded Polyanhydride Nanoparticles to Combat Gemcitabine Resistance in Pancreatic Cancer. DOI 10.1007/s40883-025-00394-0↗
- Paper Emerging Role of miR-345 and Its Effective Delivery as a Potential Therapeutic Candidate in Pancreatic Cancer and Other… DOI 10.3390/pharmaceutics13121987↗
- Satyanarayana Rachagani · 3 shared papers, 2021–2025 · strength 0.63
- Paper Niclosamide nanoparticles enhance pancreatic cancer sensitivity to gemcitabine via HIF-1α inhibition. DOI 10.1016/j.isci.2025.114088↗
- Paper Niclosamide-Loaded Polyanhydride Nanoparticles to Combat Gemcitabine Resistance in Pancreatic Cancer. DOI 10.1007/s40883-025-00394-0↗
- Paper Emerging Role of miR-345 and Its Effective Delivery as a Potential Therapeutic Candidate in Pancreatic Cancer and Other… DOI 10.3390/pharmaceutics13121987↗
- Balaji Narasimhan · 3 shared papers, 2022–2025 · strength 0.62
- Paper Niclosamide nanoparticles enhance pancreatic cancer sensitivity to gemcitabine via HIF-1α inhibition. DOI 10.1016/j.isci.2025.114088↗
- Paper Niclosamide-Loaded Polyanhydride Nanoparticles to Combat Gemcitabine Resistance in Pancreatic Cancer. DOI 10.1007/s40883-025-00394-0↗
- Paper Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies. DOI 10.7150/thno.64805↗
- Susheel Kumar Nethi · 2 shared papers, 2025 · strength 0.49
- Venugopal Gunda · 2 shared papers, 2025 · strength 0.49
- Metin Uz · 1 shared paper, 2021 · strength 0.14
- Aliasger K Salem · 1 shared paper, 2022 · strength 0.13
- Shailendra Kumar Gautam · 1 shared paper, 2022 · strength 0.13
- Luman Liu · 1 shared paper, 2022 · strength 0.13
- Maneesh Jain · 1 shared paper, 2022 · strength 0.13
- Joyce C. Solheim · 1 shared paper, 2022 · strength 0.13
- Sushil Kumar K · 1 shared paper, 2022 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.